Metsera stock soars as Novo Nordisk, Pfizer sweeten bids in takeover battle By Investing.com
Update: 2025-11-04
Description
Metsera Inc becomes the center of Wall Street attention as Novo Nordisk and Pfizer engage in a high-stakes bidding war for the biotech firm's obesity drug pipeline. Novo Nordisk raises its offer to around $10 billion, while Pfizer boosts its cash offer to $8.1 billion. Metsera's board chooses Novo's proposal, but Pfizer has a short window to counter with a stronger deal. Tensions escalate with Pfizer filing lawsuits against Metsera and Novo Nordisk, accusing Novo of breaking agreements and antitrust regulations. The future of obesity medicine is at stake in this intense rivalry.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
